A 41-year-old with COVID-19 on day 6 of symptoms has high risk but significant drug-drug interactions preclude ritonavir-boosted nirmatrelvir. eGFR 95...

Question

A 41-year-old with COVID-19 on day 6 of symptoms has high risk but significant drug-drug interactions preclude ritonavir-boosted nirmatrelvir. eGFR 95. What is the next preferred option?

Accepted Answer

Three-day IV remdesivir initiated now

Answer

Molnupiravir initiated now

Answer

Convalescent plasma

Answer

Monoclonal antibodies (any available)

Answer

No antiviral therapy

us-abfm MCQ (SBA): COVID-19 (Outpatient)

A 41-year-old with COVID-19 on day 6 of symptoms has high risk but significant drug-drug interactions preclude ritonavir-boosted nirmatrelvir. eGFR 95. What is the next preferred option?